MSK-rheum drugs Flashcards

(41 cards)

1
Q

name the non-depolarizing neuromuscular blockers

A

-curiums: atracurium and cisatracurium
D-tubocurarine
-curoniums: pancuronium, rocuronium, vecuronium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the difference between atracurium and cisatracurium

A

atracurium produces toxic metabolite responsible for seizures: avoided with cisatracurium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

which are the most potent non-depolarizing NMBs?

A

pancuronium and vecuronium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

how do non-depolarizing NMBs work?

A

prevent opening of channel, prevents any activation of muscle contraction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

how does succinylcholine works as depolarizing NMB?

A

stimulates opening of receptor channel then prevents closing of it and blocks it, prevents repolarization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

how do acetylcholinesterase inhibitors affect succinylcholine?

A

Phase 1: increases initial muscle contraction via increased Ach
Phase 2: antagonizes/reverses depolarization by increased Ach displacing succinylcholine
-give ACHEIs when some recovery evident to speed it up

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the following drugs effects on heart due to binding cardiac M receptors:
pancuronium, rocuronium, succinylcholine

A

pancuronium: moderate stimulation of heart (block M receptor)
rocuronium: slight stimulation of heart
succinylcholine: heart block (stimulate M receptor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

which 3 NMBs stimulate histamine release?

A

atracurium, tubocurarine, succinylcholine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are edrophonium, neostigmine, pyridostigmine and what are they used for?

A

anticholinesterase inhibitors

-reverse effects of NMB by preventing metabolism of Ach

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is given with AchEIs and why?

A

antimuscarinics to reduce off-target stimulation of muscarinic receptors
glycopyrrolate with stigmines, atropine with edrophonium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is suggamadex?

A

reversal agent for steroid-derived non-depolarizing NMBs (-curoniums)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is the difference b/w suggamadex and AchEIs?

A

suggamadex can reverseany depth of neuromuscular blockade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

which NSAID is not used to treat rheumatoid/psoriatic arthritis and why? what is it used for?

A

acetaminophen: no anti-inflammatory effects

may be used for OA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

which NSAID has the shortest half-life as well as the lowest risk for GI toxicity amongst traditional NSAIDs?

A

diclofenac

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

which two NSAIDs have the highest risk for GI toxicity

A

ibuprofen and naproxen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

which two NSAIDs are associated with CV events in high dose regimens?

A

ibuprofen and diclofenac

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

which two NSAIDs have long half-lives?

A
naproxem
piroxicam (longest)
18
Q

which NSAID is particularly CV friendly?

19
Q

how are NSAIDs metabolized and excreted? exception?

A

hepatic metabolism
renal elimination of very little parental drug
-ketorolac is eliminated 58% unchanged in urine

20
Q

which NSAIDs are most effective?

A

trick question: none more effective than the other

21
Q

what is the general treatment steps in RA?

A
  1. methotrexate (maybe with steroid/NSAID)
  2. hydroxychloroquine if milder case
    - lefulnomide, sulfasalazine
  3. biologics if these fail (use w/ or w/o methotrexate)
22
Q

what is the MOA of methotrexate in RA?

A

anti-inflammatory:

  • DHFR inhibition
  • increased adenosine: inhibits lymphocyte proliferation and secretion of IL-1, TNF, IFN
23
Q

what is the MOA for hydroxychloroquine?

A

anti-inflammatory:

  • increases intracellular vacuole pH
  • can’t digest antigens and present to CD4’s
  • no activation of CD4 cells
24
Q

what is the MOA for leflunomide?

A

inhibits step in de novo pyrimidine synthesis

  • causes cell cycle arrest in lymphocytes
  • Ig production is suppressed
25
what is the MOA for sulfasalazine?
metabolized to mesalamine: inhibits PG/LT production = anti-inflammatory
26
adalimumab
anti-TNF-alpha
27
certolizumab
anti-TNF-alpha
28
etanercept
anti-TNF-alpha
29
golimumab
anti-TNF-alpha
30
infliximab
anti-TNF-alpha
31
anakinra: MOA and use
for RA | competitively inhibits IL-1 binding to IL-1R1
32
tocilizumab: MOA and use
for RA | anti-IL-6-receptor antibody
33
abatacept: MOA and use
for RA | binds CD80/86 and prevents T cell stimulatory signal from CD28 (fusion of CTLA-4 to Ig Fc fragment)
34
rituximab: MOA and use
for RA | anti-CD20, induces B cell lysis
35
apremilast: MOA and use
for psoriatic arthritis | PDE4 inhibitor: improves swelling of arthritis and plaques of psoriasis
36
colchicine: MOA and uses
for gouty arthritis only: prophylaxis and termination of attacks binds tubulin, prevents polymerization of tubules -prevents PMN motility/activity and thus inflammation
37
indomethacine: use and MOA
relieve acute attack of gouty arthritis | COX-inhibitor
38
allopurinol: use and MOA
reduce plasma uric acid and urinary excretion of UA prevent uric acid nephrolithiasis inhibits xanthine oxidase: xanthine and hypoxanthine are more soluble
39
febuxostat: use and MOA
lower urate levels in patients who can't tolerate allopurinol due to renal impairment potent inhibitor of xanthine oxidase
40
probenecid: use and MOA
increases uric acid excretion in patients where it's too low | blocks post-secretory reabsorption by inhibiting organic acid transporter
41
pegloticase: 2 uses, MOA
1. unseemly tophi 2. severe gout where other therapy ineffective or contraindicated - formulation of urate oxidase, which converts UA to much more soluble allantoin